Physician profile
Amie M Sun-Wright
NPI 1427250349
$2,573.69
in general payments reported to CMS, 2019-2025
30 companies · $521 in 2025
The $521 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $321 · 2020: $50.97 · 2021: $152 · 2022: $375 · 2023: $445 · 2024: $707 · 2025: $521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,674.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,673.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $435.77 | 2019-2025 | Repatha, Krystexxa, Otezla |
| Novo Nordisk INC | $416.31 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $239.01 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals Lp | $188.27 | 2019-2024 | Airsupra, Breztri |
| Bausch Health US, LLC | $143.43 | 2021-2025 | Aplenzin |
| Si-Bone, INC. | $138.21 | 2023 | |
| Abbott Laboratories | $130.75 | 2019-2024 | Freestyle Libre 3, Proclaim, Octrode |
| Ucb, INC. | $125.00 | 2019 | |
| Glaxosmithkline, LLC. | $110.17 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $88.38 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.03 | 2022-2025 | Jardiance |
| Medtronic, INC. | $64.79 | 2021-2025 | Minimed 780g |
| Exact Sciences Corporation | $64.36 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Global Blood Therapeutics, INC. | $52.83 | 2022 | |
| Inspire Medical Systems, INC. | $38.42 | 2024-2025 | Inspire |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $32.71 | 2019-2024 | |
| Esperion Therapeutics, INC. | $24.76 | 2021 | |
| Phadia US INC. | $24.24 | 2024 | Immunocap |
| Edwards Lifesciences Corporation | $20.97 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Bayer Healthcare Pharmaceuticals INC. | $19.20 | 2025 | |
| Nevro Corp. | $18.97 | 2024 | Senza |
| Merck Sharp & Dohme LLC | $18.92 | 2022 | |
| Astellas Pharma US INC | $18.04 | 2019 | |
| Philips North America LLC | $17.90 | 2024 | (Ak6) Vest Therapy |
| Paratek Pharmaceuticals, INC. | $17.29 | 2025 | Nuzyra |
| Tolmar, INC. | $15.70 | 2025 | Jatenzo |
| Antares Pharma, INC. | $13.47 | 2025 | Xyosted |
| Teva Pharmaceuticals USA, INC. | $11.79 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amie Sun-Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.